Emilia Scalzulli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention	INTERNATIONAL JOURNAL OF CARDIOLOGY	2019
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life	ANNALS OF HEMATOLOGY	2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice	ANNALS OF HEMATOLOGY	2019
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib	ONCOLOGY RESEARCH AND TREATMENT	2019
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia	THERAPEUTIC ADVANCES IN HEMATOLOGY	2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice	ANNALS OF HEMATOLOGY	2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart	HEMATOLOGICAL ONCOLOGY	2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention	INTERNATIONAL JOURNAL OF CARDIOLOGY	2019
Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols	BLOOD	2019
Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib	ONCOLOGY RESEARCH AND TREATMENT	2019
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life	ANNALS OF HEMATOLOGY	2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis	ANNALS OF HEMATOLOGY	2019
Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome	HEMATOLOGICAL ONCOLOGY	2019
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events	ANNALS OF HEMATOLOGY	2018
Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice	BLOOD	2018
Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice	BLOOD	2018
. Myeloma; living better and living longer - a look at the advances.	EXPERT REVIEW OF QUALITY OF LIFE IN CANCER CARE	2017
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life	AMERICAN JOURNAL OF HEMATOLOGY	2017
Incidence and outcome of infections after unrelated cord blood transplantation in patients with hematological malignancies: a long-term single center experience	Bone Marrow Transplantation	2015